http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2254105-C1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-007 |
| filingDate | 2003-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2005-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf9fa2d7bfdc9f9f67b5bed120121086 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d488c8603fcccff544a007e6493dab8f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9cafd25f6ecbd83ea168f26bfe2f5ac http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_edaa825f66c92b41bfe031d0314c205c |
| publicationDate | 2005-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2254105-C1 |
| titleOfInvention | Surgical method for treating the cases of macular rupture complicated with ablatio retinae |
| abstract | FIELD: medicine. n SUBSTANCE: method involves making access to central zone of eye fundus. Posterior hyaloid membrane is exfoliated and excised. Adjacent vitreous body layers are withdrawn. Liquid perfluororganic compound is supplied to optic nerve disk in the amount of 1,0-1,5 ml. Epiretinal membrane is removed in the central retinal zone. Perfluororganic compound is exchanged for salt solution and internal boundary membrane is stained with 0.05% trepan blue solution. Notches are produced on the internal boundary membrane from temporal side away from macula. Notched edge is lifted. Perfluororganic compound is introduced into optic nerve disk in the same amount and maculorhexis is carried out in catching the lifted internal boundary membrane zone with instrument. The internal boundary membrane being removed, final stage-by-stage vitrectomy moving to iridolenticular diaphragm, alternating with perfluororganic compound administration and epiretinal membrane removal excision in perfluororganic compound medium. After having filled the vitreous body cavity with perfluororganic compound near dentate line in point of detached retina maximum height, draining retinotomy is carried out by means of diathermocoagulator. Subretinal fluid being discharged, endolaser coagulation around drainage zone by adding perfluororganic compound to fill the whole vitreous body cavity volume. Perfluororganic compound is substituted with air. Patient ex tempore blood application is carried out on macular rupture zone. The procedure is repeated three times, with blood serum being removed each time. Air is substituted with prolonged sorption time gas. n EFFECT: enhanced effectiveness of treatment; reduced risk of traumatic complications. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2583597-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2563439-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2563452-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2563438-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2754514-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2583605-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2686419-C1 |
| priorityDate | 2003-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 29.